SequelSEC

Cadrenal Therapeutics, Inc. CVKD

Pharmaceutical Preparations · CIK 0001937993 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$13.46M
Fiscal year ended 2025-12-31
Free cash flow
-$12.61M
Fiscal year ended 2025-12-31

Cadrenal Therapeutics, Inc. (CVKD) reported net income of -$13.24M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Cadrenal Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Cadrenal Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailable$220.10K
Gross profitUnavailableUnavailableUnavailable
Operating income-$13.46M-$10.96M-$7.63M
Net income-$13.24M-$10.65M-$8.36M
Research & development$4.10M$4.21M$4.08M
Weighted-average diluted sharesshares 1.99Mshares 1.22MUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-6.64$-8.73$-9.29
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$9.35M$6.75M$3.55M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Cadrenal Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$4.01M$10.02M$8.40M
Total assets$4.33M$10.12M$8.52M
Current assets$4.32M$10.11M$8.49M
Total liabilities$1.59M$2.68M$826.88K
Current liabilities$1.59M$2.68M$826.88K
Total equity incl. NCI$2.74M$7.44M$7.69M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$650.66K$1.50M$167.32K

Cash flow

Cadrenal Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$12.60M-$7.36M-$3.53M
Capital expenditures$5.10K$6.54K$3.25K
Investing cash flow-$5.10K-$6.54K-$3.25K
Financing cash flow$6.60M$8.98M$11.90M
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$1.94M$1.42M$710.38K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Cadrenal Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$12.61M-$7.36M-$3.53M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio2.72x3.77x10.27x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CVKD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.